Sugi Predict

Sugi Predict / Compounds / SCHEMBL1399775

SCHEMBL1399775

SCHEMBL1399775

COC(=O)c1cccc(-c2cccnc2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.74
▸ CYP11B1 P15538 1/20 0.74
▸ CYP11B2 P19099 1/20 0.74
▸ ALDH1A1 P00352 1/20 0.68
▸ NEK1 Q96PY6 4/20 0.67
▸ KMO O15229 1/20 0.67
▸ SLC2A1 P11166 1/20 0.65
▸ ABL1 P00519 1/20 0.62
▸ BCR P11274 1/20 0.62
▸ SRC P12931 1/20 0.62
▸ NR4A2 P43354 2/20 0.59
▸ GABRG2 P18507 1/20 0.57
▸ GABRB3 P28472 1/20 0.57
▸ GABRA5 P31644 1/20 0.57
▸ GABRA3 P34903 1/20 0.57
▸ KDM4E B2RXH2 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ ABCG2 Q9UNQ0 1/20 0.56
▸ CDK8 P49336 1/20 0.56
▸ CA12 O43570 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3511516 0.89 CYP19A1 (0.68) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1
SCHEMBL10028698 0.89 CYP19A1 (0.68) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1
SCHEMBL31704881 0.88 ALDH1A1 (0.68) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1
SCHEMBL31705350 0.88 ALDH1A1 (0.68) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1
SCHEMBL3714867 0.88 ALDH1A1 (0.68) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1
SCHEMBL29771391 0.88 ALDH1A1 (0.68) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1
SCHEMBL10028685 0.86 ALDH1A1 (0.66) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1
SCHEMBL13044192 0.86 CYP11B1 (0.64) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1
SCHEMBL5562732 0.86 NEK1 (0.65) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1
SCHEMBL4509922 0.85 CYP11B2 (1.00) CYP19A1CYP11B1CYP11B2ALDH1A1NEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2026-01-29 — — US disclosed
US-12534452-B2 N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient KAINOS MEDICINE, INC. (KR) 2026-01-27 — — US disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
US-20220348560-A1 N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT KAINOS MEDICINE, INC. (KR) 2022-11-03 — — US disclosed
CN-111978200-B Biphenylamide derivative, preparation method and application 湖北省生物农药工程研究中心 2022-09-13 — — CN disclosed
EP-4038062-A1 N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT Kainos Medicine, Inc. (KR) 2022-08-10 — — EP disclosed
CN-114466844-A N- (1H-imidazol-2-yl) benzamide compounds and pharmaceutical compositions containing the same as active ingredient 康佳诺医疗科技发展有限公司 2022-05-10 — — CN disclosed
US-5824691-A CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-10-20 — — US disclosed
CN-1123545-A Guanidine derivatives as inhibitors of Na+/H+ exchange in cells FUJISAWA PHARMACEUTICAL CO (JP) 1996-05-29 — — CN disclosed
EP-0699185-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-03-06 — — EP disclosed
WO-1994026709-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-24 — — WO disclosed
US-4937346-A Phenyl-azacykloalkanes Carlsson, Per Arvid Emil (SE) 1990-06-26 — — US disclosed
US-4719219-A Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders Carlsson, Per A. E. (SE) 1988-01-12 — — US disclosed
US-4426386-A CNS DISORDERS ASTRA LAKEMEDEL AKTIEBOLAG (SE) 1984-01-17 — — US disclosed
EP-0084920-A2 New compounds useful as intermediates or starting materials for preparation of therapeutically useful phenyl-azacycloalkanes Carlsson, Per Arvid Emil (SE) 1983-08-03 — — EP disclosed
EP-0030526-A1 New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds Astra Läkemedel Aktiebolag (SE) 1981-06-17 — — EP disclosed
WO-1981001552-A1 NEW PHENYL-AZACYCLOALKANES ASTRA LAEKEMEDEL AB (SE) 1981-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 CYP19A1 1326/4885CYP11B1 117/4885CYP11B2 135/4885
US-20220348560-A1 N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT IRAK4, IRAK1, IRAK2 CYP19A1 2132/4885CYP11B1 3201/4885CYP11B2 3336/4885
US-12534452-B2 N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient IRAK4, IRAK1, IRAK2 CYP19A1 2601/4885CYP11B1 2050/4885CYP11B2 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.